STOCK TITAN

Oragenics Inc - OGEN STOCK NEWS

Welcome to our dedicated news page for Oragenics (Ticker: OGEN), a resource for investors and traders seeking the latest updates and insights on Oragenics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oragenics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oragenics's position in the market.

Rhea-AI Summary
Oragenics, Inc. (OGEN) completes a public offering, raising $2.1 million for the development of ONP-002, a neurosteroid drug for mild traumatic brain injuries. ThinkEquity and Laidlaw & Company act as book-running managers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
Oragenics, Inc. (OGEN) announces the pricing of a public offering of 1,400,000 shares of common stock at $1.50 per share, raising $2.1 million for the development of a neurosteroid drug compound to treat mild traumatic brain injuries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.04%
Tags
offering
-
Rhea-AI Summary
Oragenics, Inc. (OGEN) announces a public offering of common stock to fund the development of ONP-002, a neurosteroid drug for treating mild traumatic brain injuries. The offering is led by ThinkEquity and Laidlaw & Company (UK) Ltd.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.04%
Tags
offering
Rhea-AI Summary
Oragenics, Inc. (NYSE American: OGEN) announced the termination of Chief Executive Officer Kimberly Murphy's employment, with her continuing as a board member. The Board appointed Charlie Pope as Executive Chairman and Michael Redmond as Interim Principal Executive Officer. The Company aims to focus on its neurology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.47%
Tags
management
-
Rhea-AI Summary
Oragenics, Inc. (OGEN) has announced the expiration of its engagement agreement with its investment bank and the decision not to extend it due to current market conditions. The company is focused on developing intranasal nanoparticle pharmaceuticals for neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.08%
Tags
none
-
Rhea-AI Summary
Oragenics, Inc. (OGEN) is preparing for a Phase II clinical trial for its lead drug candidate, ONP-002, designed to target the brain through intranasal delivery for the treatment of mild Traumatic Brain Injury. The drug has shown promise in animal models and is expected to have a large safety margin in the upcoming trial. With an estimated 69M concussions reported annually worldwide, the potential market for this treatment is significant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
clinical trial
Rhea-AI Summary
Oragenics, Inc. (NYSE American: OGEN) has terminated its 'at-the-market' equity offering program, with the termination to take effect on January 30, 2024. The Company will make no sales under the ATM offering during this period. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
none
-
Rhea-AI Summary
Oragenics, Inc. (NYSE American: OGEN) has completed the acquisition of assets related to Odyssey Health, Inc.'s proprietary neurological drug therapies and technologies, including ONP-002 and a unique nasal delivery device. The acquisition aims to develop innovative treatments for moderate-to-severe concussion and Niemann Pick Type-C Disease (NPC), addressing a significant market opportunity. Michael Redmond has been named President of Oragenics, bringing 35 years of commercial experience with medical device companies to oversee the growth of Oragenics' neurology product pipeline and intranasal drug delivery technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.43%
Tags
acquisition
-
News
Rhea-AI Summary
Oragenics, Inc. announces the acquisition of Odyssey Health, Inc.'s lead assets, including proprietary neurological drug therapies. The assets have potential for enhancing shareholder value and expanding the market reach. The global market for concussion treatment is valued at $6.9 billion in 2020 and projected to reach $8.9 billion by 2027. The market for Niemann Pick Disease Type C is projected to increase from $128 million in 2022 to $188 million in 2031. The acquisition also brings a team of talented scientists to enhance research and development efforts. Proposal 3 of the 2022 Annual Meeting involves increasing the authorized common stock to support the acquisition and raise capital for ongoing research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
Rhea-AI Summary
Oragenics, Inc. announces the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
management
Oragenics Inc

NYSE:OGEN

OGEN Rankings

OGEN Stock Data

4.41M
2.26M
33.91%
2.02%
7.41%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Tampa

About OGEN

oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies. offerings are based on the probiora3 technology and brands include evoraplus™ is a new, one-of-a-kind probiotic mint that naturally supports gum and tooth health while freshening breath and whitening teeth. oragenics has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.